Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Santiago Ponce Aix; Denis Talbot; Ramaswamy Govindan; Manuel Cobo Dols; Pieter E. Postmus; Conrad Lewanski; Jaafar Bennouna; Juergen R. Fischer; Oscar Juan-Vidal; David J. Stewart; Andrea Ardizzoni; Rafia Bhore; Marianne Wolfsteiner; Martin Reck; Teng Jin Ong; Daniel Morgensztern

doi:10.2217/fon-2019-0796

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Santiago Ponce Aix
, Denis Talbot
, Ramaswamy Govindan
, Manuel Cobo Dols
, Pieter E. Postmus
, Conrad Lewanski
, Jaafar Bennouna
, Juergen R. Fischer
, Oscar Juan-Vidal
, David J. Stewart
, Andrea Ardizzoni
, Rafia Bhore
, Marianne Wolfsteiner
, Martin Reck
, Teng Jin Ong
, Daniel Morgensztern

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

Original language	English
Pages (from-to)	749-762
Number of pages	14
Journal	Future Oncology
Volume	16
Issue number	12
DOIs	https://doi.org/10.2217/fon-2019-0796
State	Published - Apr 2020

Keywords

EORTC QLQ-C30
EQ-5D-5L
durvalumab
lung cancer symptom scale
nab-paclitaxel
non-small cell lung cancer
quality of life

Access to Document

10.2217/fon-2019-0796

Cite this

Ponce Aix, S., Talbot, D., Govindan, R., Dols, M. C., Postmus, P. E., Lewanski, C., Bennouna, J., Fischer, J. R., Juan-Vidal, O., Stewart, D. J., Ardizzoni, A., Bhore, R., Wolfsteiner, M., Reck, M., Ong, T. J., & Morgensztern, D. (2020). Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Future Oncology, 16(12), 749-762. https://doi.org/10.2217/fon-2019-0796

@article{9110969eb9334e40a1a827a7ea859331,

title = "Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer",

abstract = "Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients \& methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56\% and 9-51\% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.",

keywords = "EORTC QLQ-C30, EQ-5D-5L, durvalumab, lung cancer symptom scale, nab-paclitaxel, non-small cell lung cancer, quality of life",

author = "\{Ponce Aix\}, Santiago and Denis Talbot and Ramaswamy Govindan and Dols, \{Manuel Cobo\} and Postmus, \{Pieter E.\} and Conrad Lewanski and Jaafar Bennouna and Fischer, \{Juergen R.\} and Oscar Juan-Vidal and Stewart, \{David J.\} and Andrea Ardizzoni and Rafia Bhore and Marianne Wolfsteiner and Martin Reck and Ong, \{Teng Jin\} and Daniel Morgensztern",

note = "Publisher Copyright: {\textcopyright} 2020 Celgene.",

year = "2020",

month = apr,

doi = "10.2217/fon-2019-0796",

language = "English",

volume = "16",

pages = "749--762",

journal = "Future Oncology",

issn = "1479-6694",

number = "12",

}

Ponce Aix, S, Talbot, D, Govindan, R, Dols, MC, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Ong, TJ & Morgensztern, D 2020, 'Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer', Future Oncology, vol. 16, no. 12, pp. 749-762. https://doi.org/10.2217/fon-2019-0796

TY - JOUR

T1 - Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

AU - Ponce Aix, Santiago

AU - Talbot, Denis

AU - Govindan, Ramaswamy

AU - Dols, Manuel Cobo

AU - Postmus, Pieter E.

AU - Lewanski, Conrad

AU - Bennouna, Jaafar

AU - Fischer, Juergen R.

AU - Juan-Vidal, Oscar

AU - Stewart, David J.

AU - Ardizzoni, Andrea

AU - Bhore, Rafia

AU - Wolfsteiner, Marianne

AU - Reck, Martin

AU - Ong, Teng Jin

AU - Morgensztern, Daniel

PY - 2020/4

Y1 - 2020/4

N2 - Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

AB - Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

KW - EORTC QLQ-C30

KW - EQ-5D-5L

KW - durvalumab

KW - lung cancer symptom scale

KW - nab-paclitaxel

KW - non-small cell lung cancer

KW - quality of life

UR - https://www.scopus.com/pages/publications/85083891500

U2 - 10.2217/fon-2019-0796

DO - 10.2217/fon-2019-0796

M3 - Article

C2 - 32228198

AN - SCOPUS:85083891500

SN - 1479-6694

VL - 16

SP - 749

EP - 762

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this